Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic To Pay $55M In HeartWare Investor Suit

Executive Summary

Device-giant Medtronic has agreed to pay $54.5m to settle a class-action suit filed by investors in HeartWare, which Medtronic bought in 2016. The plaintiffs say HeartWare misled investors about the safety of a miniaturized heart pump under development.

You may also be interested in...



Medtronic Ups Its Heart-Failure Competitive Strength With HeartWare Buy

The deal gives Medtronic its first ventricular-assist devices and gives struggling HeartWare a needed boost.

HeartWare Updates Status Of Battles On Several Fronts

HeartWare is counting on its established HVAD technology to carry it through a difficult period as it struggles to relaunch the clinical trial of the MVAD miniaturized ventricular assist device.

Merit Medical To Pay $18M To Settle Kickback Case

The US Department of Justice says the company provided advertising assistance and educational grants to health care providers that used its embolization devices.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel